Iradimed (IRMD) and The Competition Head to Head Review

Iradimed (NASDAQ: IRMD) is one of 104 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its rivals? We will compare Iradimed to related companies based on the strength of its institutional ownership, risk, analyst recommendations, dividends, valuation, profitability and earnings.

Volatility & Risk

How to Become a New Pot Stock Millionaire

Iradimed has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Iradimed’s rivals have a beta of 0.80, indicating that their average share price is 20% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Iradimed and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Iradimed 0 0 2 0 3.00
Iradimed Competitors 494 1870 3733 112 2.56

Iradimed currently has a consensus target price of $17.50, indicating a potential upside of 21.95%. As a group, “Surgical & medical instruments” companies have a potential upside of 14.51%. Given Iradimed’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Iradimed is more favorable than its rivals.

Profitability

This table compares Iradimed and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Iradimed 2.17% 3.03% 2.58%
Iradimed Competitors -61.96% -46.96% -18.08%

Valuation and Earnings

This table compares Iradimed and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Iradimed $23.08 million $490,000.00 179.38
Iradimed Competitors $1.54 billion $111.91 million -139.58

Iradimed’s rivals have higher revenue and earnings than Iradimed. Iradimed is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

16.3% of Iradimed shares are owned by institutional investors. Comparatively, 48.3% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 60.1% of Iradimed shares are owned by insiders. Comparatively, 16.7% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Iradimed beats its rivals on 9 of the 13 factors compared.

Iradimed Company Profile

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Hudson Technologies  Downgraded by ValuEngine to Sell
Hudson Technologies Downgraded by ValuEngine to Sell
Escalade  Lowered to “Hold” at ValuEngine
Escalade Lowered to “Hold” at ValuEngine
Sailpoint Technologies’  Buy Rating Reaffirmed at Jefferies Group
Sailpoint Technologies’ Buy Rating Reaffirmed at Jefferies Group
Beazer Homes USA  Downgraded by ValuEngine to Hold
Beazer Homes USA Downgraded by ValuEngine to Hold
Tao  Achieves Market Cap of $14.81 Million
Tao Achieves Market Cap of $14.81 Million
Ellie Mae  Raised to “Hold” at Zelman & Associates
Ellie Mae Raised to “Hold” at Zelman & Associates


Leave a Reply

© 2006-2018 Ticker Report. Google+.